Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years

Understanding long-term effectiveness of herpes zoster (HZ) vaccine is critical for determining vaccine policy. 176 078 members of Kaiser Permanente ≥60 years vaccinated with HZ vaccine and three matched unvaccinated members were included. Hazard ratios and 95% confidence intervals (CIs) associated...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases Vol. 213; no. 12; pp. 1872 - 1875
Main Authors Tseng, Hung Fu, Harpaz, Rafael, Luo, Yi, Hales, Craig M., Sy, Lina S., Tartof, Sara Y., Bialek, Stephanie, Hechter, Rulin C., Jacobsen, Steven J.
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 15.06.2016
Subjects
Aged
Herpes Zoster - immunology
Herpes Zoster Vaccine - immunology
Humans
Immunization, Secondary
Middle Aged
Policy Making
Proportional Hazards Models
Treatment Outcome
Vaccination
VIRUSES
varicella zoster virus
adult vaccination
herpes zoster
shingles
Online AccessGet full text

Cover

More Information
Summary:Understanding long-term effectiveness of herpes zoster (HZ) vaccine is critical for determining vaccine policy. 176 078 members of Kaiser Permanente ≥60 years vaccinated with HZ vaccine and three matched unvaccinated members were included. Hazard ratios and 95% confidence intervals (CIs) associated with vaccination at each year following vaccination were estimated by Cox regression model. The effectiveness of HZ vaccine decreased from 68.7% (95% CI, 66.3%–70.9%) in the first year to 4.2% (95% CI, –24.0% to 25.9%) in the eighth year. This rapid decline in effectiveness of HZ vaccine suggests that a revaccination strategy may be needed, if feasible.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiw047